-
Capital, M&A & Industry Strategy4 weeks agoFacilitating Collaboration Across CDER
C3TI facilitates collaboration across CDER through multi-channel engagement and a network of champions.
-
Capital, M&A & Industry Strategy4 weeks agoFoghorn lays off 40% of staff after Lilly collaboration ends
Foghorn Therapeutics and Eli Lilly teamed up in 2021 to develop and commercialize oncology products. The biotech’s layoffs will leave the company with 65 employees as...
-
Capital, M&A & Industry Strategy4 weeks agoSanofi pays Regeneron $1B upfront to continue search for Dupixent successor
Sanofi and Regeneron have had a long and “sometimes contentious” partnership, BMO Capital Markets noted, as the companies contend with the looming loss of exclusivity of...
-
Capital, M&A & Industry Strategy4 weeks agoM&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buy
After a frantic second quarter, M&A steadied with just under $30 billion across 22 total transactions, according to a BioSpace analysis.
-
Capital, M&A & Industry Strategy4 weeks agoSanofi forges new $8bn pact with Regeneron
Sanofi's long-running R&D alliance with Regeneron has gone up a gear with a new deal – including a $1bn upfront payment – that spans four new...
-
Capital, M&A & Industry Strategy4 weeks agoSTAT+: Sanofi, Regeneron expand partnership after Dupixent success
Sanofi and Regeneron have re-upped their collaboration pact, aiming to build on the blockbuster success of the drug Dupixent.
-
Capital, M&A & Industry Strategy1 month agoOBIO marks $704m funding milestone for Canadian health tech ventures
The initiative is supported by the Government of Canada through the Federal Economic Development Agency for Southern Ontario. It is designed to help post-seed health science...
-
Capital, M&A & Industry Strategy1 month agoTrend of women-led M&A fades in 2026 with just two deals so far
Last year, 11 major M&A deals were signed with women-led biotechs. The industry is nowhere near on track to meet that bar for 2026.
-
Capital, M&A & Industry Strategy1 month agoNovo gets shot at weekly obesity pill as Hengrui gets another MNC deal
BIOCENTURY | DEALSNOVO GETS SHOT AT WEEKLY OBESITY PILL AS HENGRUI GETS ANOTHER MNC DEALNovo adds once-weekly oral GLP1R/GIPR dual agonist for $300M up front
-
Capital, M&A & Industry Strategy1 month agoMerck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue
Merck agreed to pay SciBrunch up to $2.13 billion consisting of $400 million upfront and the remainder in payments tied to achieving milestones across multiple indications....
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
